Atrial fibrillation (A-Fib or AF) involves quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. Treatments for atrial fibrillation may include medications and other interventions to try to alter the heart’s electrical system. Atrial fibrillation (AF) is one of the most commonly occurring cardiac rhythm conditions, and are potentially life threatening and expensive to treat.
The global atrial fibrillation market report provides market size estimates (Revenue USD million – 2014 to 2021) for key market segments based on treatment type (pharmacological – anti-arrhythmic drugs, anti-coagulant drugs and non-pharmacological – catheter ablation based on cryoablation, HIFU, laser, microwave and radiofrequency, maze surgery, and electric cardioversion), and forecasts growth trends (CAGR% – 2017 to 2021).
The global atrial fibrillation market segmentation is based on geography (regional and country based). The global atrial fibrillation market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global atrial fibrillation market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global atrial fibrillation market and profiled in the report are St. Jude Medical, Boehringer Ingelheim, Boston Scientific Corporation, AtriCure, Inc., Johnson & Johnson and Bayer (Xeralto), Sanofi, CardioFocus, Endoscopic Technologies, Bristol Myers-Pfizer, Biosense Wesbter and others.